Tekla Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Tekla Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$1.42M	Hold	148,874	–	–	0.06%	121
2023 Q1	$1.64M	Hold	148,874	–	–	0.06%	127
2022 Q4	$2.2M	Hold	148,874	–	–	0.08%	111
2022 Q3	$2.85M	Hold	148,874	–	–	0.12%	100
2022 Q2	$3.17M	Buy	148,874 +17,241	+13%	+$354K	0.12%	101
2022 Q1	$2.54M	Hold	131,633	–	–	0.09%	119
2021 Q4	$2.73M	Hold	131,633	–	–	0.09%	120
2021 Q3	$3.15M	Hold	131,633	–	–	0.1%	125
2021 Q2	$3.59M	Hold	131,633	–	–	0.12%	133
2021 Q1	$3.81M	Buy	+131,633	New	+$4.11M	0.13%	136

Other funds holding ARQT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Tekla Capital Management's ARQT Position: Q2 2023 in Review

Tekla Capital Management held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2023 at 148,874 shares worth $1.42M. The position accounts for 0.06% of the portfolio, ranked #121.

Tekla Capital Management first reported a position in ARQT in Q1 2021 and has held it in 10 quarters since. The position peaked at $3.81M in Q1 2021. 136 funds tracked by Wall St. Rank hold ARQT as of Q2 2023.

Tekla Capital Management held 148,874 shares of Arcutis Biotherapeutics worth $1.42M as of Q2 2023.
Tekla Capital Management left its Arcutis Biotherapeutics share count unchanged in Q2 2023.
Arcutis Biotherapeutics made up 0.06% of Tekla Capital Management's portfolio in Q2 2023, its #121 holding.
Tekla Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2021 and has held it in 10 quarters since.
Tekla Capital Management's Arcutis Biotherapeutics position peaked at $3.81M in Q1 2021.
136 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.